- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523727
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Akebia Medical Information
- Phone Number: 1-844-445-3799
- Email: medicalinfo@akebia.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham (UAB) - Children's of Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Phoenix Childrens Hospital
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- University of California, San Francisco (UCSF) - Department of Nephrology
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
-
Florida
-
Tampa, Florida, United States, 33606
- Recruiting
- University of South Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospital - Kansas City
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87110
- Recruiting
- University of New Mexico
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- University of Utah
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 6 years to <17 years at Screening.
- Weight ≥ 20 kilograms (kg) (dry weight for dialysis participants) at Screening.
- Chronic kidney disease (CKD) requiring chronic dialysis (i.e., hemodialysis or peritoneal dialysis), or CKD not on dialysis with an estimated glomerular filtration rate (eGFR) <30 milliliters per minute (mL/min)/1.73 meters squared (m^2) at Screening.
- Documented history of CKD-related hyperphosphatemia for at least 3 months prior to the screening visit.
If participant is or is not on phosphate binder(s) at Visit 1, serum phosphorus must be:
- 6 to <13 years: >5.8 milligrams per deciliter (mg/dL).
- 13 to <17 years: >4.5 mg/dL.
- If participant is on phosphate binder(s) at Visit 1, and serum phosphorus is not greater than the above stated age-limit criteria, approximately 1 to 4-weeks of washout period is required and at Visit 1a or Visit 1b, serum phosphorus must be greater than the age above stated age-limit criteria.
- Transferrin saturation (TSAT) <50%.
- Parent/legal guardian must be willing and able to give written informed consent, and child (participant) willing and able to give age-appropriate assent according to local regulatory requirements.
- Female participants of childbearing potential, defined as post menarche and not surgically sterile, must have a negative serum pregnancy test.
Dialysis adequacy stable on current mode of dialysis prior to screening and agree to maintain dialysis prescription for the duration of the pharmacodynamic assessment period unless changes are needed for safety. A minimum dialysis adequacy (dialysis clearance of urea-dialysis time/volume of distribution of urea [Kt/V]), defined by the following:
- Hemodialysis adequacy: single-pool Kt/V ≥1.2 for at least 1 hemodialysis session within 2 months.
- Peritoneal dialysis: At least 1Kt/V reading ≥1.8 within 4 months.
Exclusion Criteria:
- Active significant GI disorder, including overt GI bleeding or active inflammatory bowel disease.
- Liver transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >3× the upper limit of normal at Screening.
- Unable to swallow pills, if participant requires tube feeding, ferric citrate must be taken orally and not administered via feeding tube.
- Non-renal cause of hyperphosphatemia.
- Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator).
- Malignancy, except for participants who have been disease-free for at least 2 years after curative therapy.
- Participants with a functioning organ transplant.
- A known allergy or intolerance to ferric citrate or any of its constituents.
Participants who do not agree to remain abstinent or assent to use a combination of 2 of the following highly effective birth control methods for at least 28 days before the first dose, during the study (including during dose interruptions), and for at least 30 days after the last dose:
- Barrier method of contraception: condoms (female or male) with or without a spermicidal agent, diaphragm, or cervical cap with spermicide.
- Intrauterine device (IUD).
- Hormone-based contraceptives which are associated with inhibition of ovulation.
- Females who are pregnant or breast-feeding other children. Participants who are being breastfed are eligible to participate in this study.
- Any other medical condition that, in the opinion of the Investigator, renders the participant unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the participant.
- The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
- Receipt of any investigational drug within 4 weeks before Screening.
- History of hemochromatosis or iron overload syndrome (e.g, hereditary sideroblastic anemia, thalassemia).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ferric citrate
Participants aged 6 to < 17 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
|
oral tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with serious and non-serious treatment-emergent adverse events (TEAEs) including gastrointestinal (GI) AEs of special interest
Time Frame: up to Week 40
|
up to Week 40
|
Number of participants with clinically significant laboratory abnormalities or changes in laboratory results
Time Frame: up to Week 40
|
up to Week 40
|
Number of participants with TEAEs leading to the discontinuation of ferric citrate
Time Frame: up to Week 40
|
up to Week 40
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in serum phosphorus to Week 12/early termination (ET)
Time Frame: Baseline; up to Week 12
|
Baseline; up to Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chief Medical Officer, Akebia Therapeutics Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Phosphorus Metabolism Disorders
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperphosphatemia
Other Study ID Numbers
- KRX-0502-308
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphosphatemia Related to Chronic Kidney Disease
-
University of Illinois at ChicagoShireCompletedHyperphosphatemia in Chronic Kidney DiseaseUnited States
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Novartis PharmaceuticalsCompletedHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement TherapyGermany, United Kingdom, Italy, Belgium, Sweden, Canada, United States, Australia, Finland, France, Norway, Puerto Rico, Switzerland
-
Astellas Pharma IncCompletedChronic Kidney Disease | Hyperphosphatemia Undergoing HemodialysisJapan
-
ArdelyxCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
Vifor Fresenius Medical Care Renal PharmaCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisChina
-
Kissei Pharmaceutical Co., Ltd.CompletedChronic Kidney Disease Requiring HemodialysisJapan
-
Assiut UniversityUnknownHyperphosphatemia
-
Panion & BF Biotech Inc.Shandong Weigao Panion Pharmaceutical Co. Ltd.CompletedEnd Stage Renal Disease | ESRD | HyperphosphatemiaChina
-
Chugai PharmaceuticalCompletedHyperphosphatemiaUnited States
Clinical Trials on ferric citrate
-
Sreedhar MandayamKeryx BiopharmaceuticalsActive, not recruitingChronic Kidney Diseases | End Stage Renal DiseaseUnited States
-
Kaiser PermanenteKeryx BiopharmaceuticalsCompletedHyperphosphatemiaUnited States
-
Keryx BiopharmaceuticalsCollaborative Study Group (CSG)CompletedHyperphosphatemia | End-stage Renal DiseaseUnited States
-
Keryx BiopharmaceuticalsCollaborative Study Group (CSG)CompletedEnd-Stage Renal Disease | HyperphosphatemiaUnited States, Puerto Rico
-
Denver Nephrologists, P.C.Keryx BiopharmaceuticalsCompletedRenal Insufficiency | Chronic Kidney Disease | Iron Deficiency Anemia | HyperphosphatemiaUnited States
-
University of California, Los AngelesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingChronic Kidney DiseasesUnited States, Canada
-
Keryx BiopharmaceuticalsCompletedHyperphosphatemia | End-stage Renal Disease | Renal Failure Chronic Requiring HemodialysisIsrael
-
Keryx BiopharmaceuticalsCompletedChronic Kidney Diseases | Iron Deficiency AnemiaUnited States
-
Keryx BiopharmaceuticalsCompletedAnemia of Chronic Kidney DiseaseIsrael
-
Keryx BiopharmaceuticalsCompletedRenal Failure | End Stage Renal Disease | ESRD | Kidney Failure | HyperphosphatemiaUnited States, Puerto Rico